

BAXTER INTERNATIONAL INC.
Key Product Line Sales
Periods Ending December 31, 2008 and 2007
(unaudited)
(\$ in millions)

	Q4 2008	Q4 2007	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2008	YTD 2007	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$506	\$463	9%	14%	\$1,966	\$1,714	15%	12%
Plasma Proteins	330	301	10%	12%	1,219	1,015	20%	15%
Antibody Therapy	309	280	10%	14%	1,217	985	24%	22%
Regenerative Medicine ¹	101	95	6%	12%	408	346	18%	15%
Other ²	113	70	61%	83%	498	510	(2%)	(8%)
Total BioScience³	\$1,359	\$1,209	12%	17%	\$5,308	\$4,570	16%	13%
Medication Delivery								
IV Therapies	\$393	\$390	1%	7%	\$1,575	\$1,402	12%	8%
Global Injectables	420	390	8%	13%	1,584	1,504	5%	3%
Infusion Systems	222	236	(6%)	(2%)	906	860	5%	4%
Anesthesia	131	126	4%	7%	464	422	10%	8%
Other	8	13	(38%)	(38%)	31	43	(28%)	(35%)
Total Medication Delivery	\$1,174	\$1,155	2%	7%	\$4,560	\$4,231	8%	5%
Renal								
PD Therapy	\$458	\$481	(5%)	(1%)	\$1,862	\$1,791	4%	(1%)
HD Therapy	99	120	(18%)	(12%)	444	448	(1%)	(5%)
Total Renal	\$557	\$601	(7%)	(3%)	\$2,306	\$2,239	3%	(2%)
Baxter excluding Transfusion Therapies	\$3,090	\$2,965	4%	9%	\$12,174	\$11,040	10%	7%
Transfusion Therapies³	\$41	\$44	(7%)	(16%)	\$174	\$223	(22%)	(25%)
TOTAL BAXTER	\$3,131	\$3,009	4%	9%	\$12,348	\$11,263	10%	6%

¹ Previously referred to as BioSurgery.

² Principally includes vaccines, sales of plasma to third parties, and recombinant FIX (BeneFIX). Sales of BeneFIX ceased as of June 30, 2007.

³ The TT business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. The TT totals above include sales of TT products through the date of divestiture, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.